Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix
Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival ra...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
QIAO Zhiqiang [verfasserIn] LI Mingmei [verfasserIn] LI Longyu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Chinesisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Zhongliu Fangzhi Yanjiu - Magazine House of Cancer Research on Prevention and Treatment, 2019, 46(2019), 8, Seite 720-723 |
|---|---|
| Übergeordnetes Werk: |
volume:46 ; year:2019 ; number:8 ; pages:720-723 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.3971/j.issn.1000-8578.2019.19.0123 |
|---|
| Katalog-ID: |
DOAJ065432975 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ065432975 | ||
| 003 | DE-627 | ||
| 005 | 20230502134530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2019 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3971/j.issn.1000-8578.2019.19.0123 |2 doi | |
| 035 | |a (DE-627)DOAJ065432975 | ||
| 035 | |a (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a QIAO Zhiqiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. | ||
| 650 | 4 | |a cervix | |
| 650 | 4 | |a small cell neuroendocrine carcinoma | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a prognosis | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a LI Mingmei |e verfasserin |4 aut | |
| 700 | 0 | |a LI Longyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Zhongliu Fangzhi Yanjiu |d Magazine House of Cancer Research on Prevention and Treatment, 2019 |g 46(2019), 8, Seite 720-723 |w (DE-627)176063638X |x 10008578 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2019 |g number:8 |g pages:720-723 |
| 856 | 4 | 0 | |u https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 |z kostenfrei |
| 856 | 4 | 0 | |u http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2019 |e 8 |h 720-723 | ||
| author_variant |
q z qz l m lm l l ll |
|---|---|
| matchkey_str |
article:10008578:2019----::lnclramnadrgoio11ainsihmlclnuon |
| hierarchy_sort_str |
2019 |
| callnumber-subject-code |
RC |
| publishDate |
2019 |
| allfields |
10.3971/j.issn.1000-8578.2019.19.0123 doi (DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 DE-627 ger DE-627 rakwb chi RC254-282 QIAO Zhiqiang verfasserin aut Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens LI Mingmei verfasserin aut LI Longyu verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 46(2019), 8, Seite 720-723 (DE-627)176063638X 10008578 nnns volume:46 year:2019 number:8 pages:720-723 https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 kostenfrei https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 46 2019 8 720-723 |
| spelling |
10.3971/j.issn.1000-8578.2019.19.0123 doi (DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 DE-627 ger DE-627 rakwb chi RC254-282 QIAO Zhiqiang verfasserin aut Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens LI Mingmei verfasserin aut LI Longyu verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 46(2019), 8, Seite 720-723 (DE-627)176063638X 10008578 nnns volume:46 year:2019 number:8 pages:720-723 https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 kostenfrei https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 46 2019 8 720-723 |
| allfields_unstemmed |
10.3971/j.issn.1000-8578.2019.19.0123 doi (DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 DE-627 ger DE-627 rakwb chi RC254-282 QIAO Zhiqiang verfasserin aut Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens LI Mingmei verfasserin aut LI Longyu verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 46(2019), 8, Seite 720-723 (DE-627)176063638X 10008578 nnns volume:46 year:2019 number:8 pages:720-723 https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 kostenfrei https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 46 2019 8 720-723 |
| allfieldsGer |
10.3971/j.issn.1000-8578.2019.19.0123 doi (DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 DE-627 ger DE-627 rakwb chi RC254-282 QIAO Zhiqiang verfasserin aut Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens LI Mingmei verfasserin aut LI Longyu verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 46(2019), 8, Seite 720-723 (DE-627)176063638X 10008578 nnns volume:46 year:2019 number:8 pages:720-723 https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 kostenfrei https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 46 2019 8 720-723 |
| allfieldsSound |
10.3971/j.issn.1000-8578.2019.19.0123 doi (DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 DE-627 ger DE-627 rakwb chi RC254-282 QIAO Zhiqiang verfasserin aut Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens LI Mingmei verfasserin aut LI Longyu verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 46(2019), 8, Seite 720-723 (DE-627)176063638X 10008578 nnns volume:46 year:2019 number:8 pages:720-723 https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 kostenfrei https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 46 2019 8 720-723 |
| language |
Chinese |
| source |
In Zhongliu Fangzhi Yanjiu 46(2019), 8, Seite 720-723 volume:46 year:2019 number:8 pages:720-723 |
| sourceStr |
In Zhongliu Fangzhi Yanjiu 46(2019), 8, Seite 720-723 volume:46 year:2019 number:8 pages:720-723 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
cervix small cell neuroendocrine carcinoma treatment prognosis Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Zhongliu Fangzhi Yanjiu |
| authorswithroles_txt_mv |
QIAO Zhiqiang @@aut@@ LI Mingmei @@aut@@ LI Longyu @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
176063638X |
| id |
DOAJ065432975 |
| language_de |
chinesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065432975</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502134530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2019.19.0123</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065432975</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">QIAO Zhiqiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cervix</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">small cell neuroendocrine carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Mingmei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Longyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">46(2019), 8, Seite 720-723</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:720-723</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2019</subfield><subfield code="e">8</subfield><subfield code="h">720-723</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
QIAO Zhiqiang |
| spellingShingle |
QIAO Zhiqiang misc RC254-282 misc cervix misc small cell neuroendocrine carcinoma misc treatment misc prognosis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| authorStr |
QIAO Zhiqiang |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063638X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
10008578 |
| topic_title |
RC254-282 Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix cervix small cell neuroendocrine carcinoma treatment prognosis |
| topic |
misc RC254-282 misc cervix misc small cell neuroendocrine carcinoma misc treatment misc prognosis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc cervix misc small cell neuroendocrine carcinoma misc treatment misc prognosis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc cervix misc small cell neuroendocrine carcinoma misc treatment misc prognosis misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Zhongliu Fangzhi Yanjiu |
| hierarchy_parent_id |
176063638X |
| hierarchy_top_title |
Zhongliu Fangzhi Yanjiu |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063638X |
| title |
Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| ctrlnum |
(DE-627)DOAJ065432975 (DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0 |
| title_full |
Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| author_sort |
QIAO Zhiqiang |
| journal |
Zhongliu Fangzhi Yanjiu |
| journalStr |
Zhongliu Fangzhi Yanjiu |
| callnumber-first-code |
R |
| lang_code |
chi |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
720 |
| author_browse |
QIAO Zhiqiang LI Mingmei LI Longyu |
| container_volume |
46 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
QIAO Zhiqiang |
| doi_str_mv |
10.3971/j.issn.1000-8578.2019.19.0123 |
| author2-role |
verfasserin |
| title_sort |
clinical treatment and prognosis of 101 patients with small cell neuroendocrine carcinoma of cervix |
| callnumber |
RC254-282 |
| title_auth |
Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| abstract |
Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. |
| abstractGer |
Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. |
| abstract_unstemmed |
Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
8 |
| title_short |
Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix |
| url |
https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123 https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0 http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm https://doaj.org/toc/1000-8578 |
| remote_bool |
true |
| author2 |
LI Mingmei LI Longyu |
| author2Str |
LI Mingmei LI Longyu |
| ppnlink |
176063638X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3971/j.issn.1000-8578.2019.19.0123 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T14:44:29.119Z |
| _version_ |
1803569457127227392 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ065432975</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502134530.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2019.19.0123</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ065432975</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ19d3dae3efb045a28a42da77f7f3a5e0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">QIAO Zhiqiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC). Methods We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29). Results In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546). Conclusion The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cervix</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">small cell neuroendocrine carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Mingmei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LI Longyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">46(2019), 8, Seite 720-723</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:46</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:720-723</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2019.19.0123</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/19d3dae3efb045a28a42da77f7f3a5e0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2019.19.0123.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">46</subfield><subfield code="j">2019</subfield><subfield code="e">8</subfield><subfield code="h">720-723</subfield></datafield></record></collection>
|
| score |
7.400567 |